Given the convenience of a once-daily injection compared to several daily injections, long-acting amylin agonists are attractive to develop and are currently being pursued as novel anti-obesity and anti-diabetes drug candidates by multiple pharmaceutical companies. This evidence concerns the gene IAPP and Obesity.